At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 54 target
Drug / intervention
Fezolinetant +1 moredrug
Likely dose
Fezolinetant 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT) for Prostate Cancer (Fez-Cap)
In Brief
A Phase 2 clinical trial evaluating Fezolinetant and Placebo for Vasomotor Symptoms and Prostate Cancer. Not yet recruiting, targeting 54 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical study to investigates the efficacy of fezolinetant in men undergoing ADT for prostate cancer in alleviating Vasomotor syndromes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVasomotor Symptoms, Prostate Cancer
CountriesHong Kong
Collaborators--
Timeline
Phase 2Not Yet Recruiting
20272028
First PostedMay 2026
Enrollment StartJul 2026
TodayJul 2026
Primary CompletionDec 2027
Study CompletionMar 2028
First PostedMay 5, 2026
Enrollment StartJul 1, 2026
Primary CompletionDec 31, 2027
Study CompletionMar 31, 2028
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2 months agoPrimary completion in 1.5 years
Interventions
Fezolinetantdrug
Fezolinetant 45 mg orally once daily for 12 weeks.
Placebodrug
Placebo orally once daily for 12 weeks.